Analysis of Predictive Factors for Early Response to Ruxolitinib in 320 Patients with Myelofibrosis From the Polish Adult Leukemia Group (PALG) Registry
Joanna Góra-Tybor(Copernicus Memorial Hospital), Krzysztof Jamroziak(Instytut Hematologii i Transfuzjologi), Magdalena Olszewska‐Szopa(Wroclaw Medical University), Ewa Bodzenta, Tomasz Sacha, Hubert Wysogląd(Jagiellonian University), Agnieszka Michalska, Marek Hus(Medical University of Lublin), Krzysztof Lewandowski(Poznan University of Medical Sciences), Malwina Mazur(University of Rzeszów), Marta Sobas, Martyna Włodarczyk(Medical University of Silesia), Olga Grzybowska‐Izydorczyk, Joanna Niesiobędzka‐Krężel(Medical University of Warsaw), Waldemar Sawicki(National Academy of Medicine), Maria Czyżewska(Nicolaus Copernicus University), Ilona Seferyńska, Maria Bieniaszewska(Gdańsk Medical University), Grzegorz Helbig(Medical University of Silesia), Elżbieta Patkowska(Institute for Transfusion Medicine), Aleksandra Gołoś(Copernicus Memorial Hospital), Damian Mikulski(Copernicus Memorial Hospital), Wojciech Świstek(University of Bydgoszcz)
Cited by 2
Related Papers
The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries
|Leukemia|2015|258
Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma
|New England Journal of Medicine|2024|162